{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:01:01Z","timestamp":1761512461643},"reference-count":32,"publisher":"American Diabetes Association","issue":"11","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,11,1]]},"abstract":"<jats:p>OBJECTIVE\u2014Type 2 diabetic patients have a high risk of coronary heart disease (CHD) and sudden death. This cardiovascular risk can be partly attributed to low levels of HDL cholesterol. The B2 allele of the CETP TaqIB polymorphism has been repeatedly reported to be associated with high HDL cholesterol levels in both healthy and type 2 diabetic subjects, but its association with CHD is unclear. We investigated the association of the CETP TaqIB polymorphism with CHD, and sudden death in particular, in a prospective cohort of type 2 diabetic patients.<\/jats:p>\n               <jats:p>RESEARCH DESIGN AND METHODS\u2014The CETP TaqIB polymorphism was genotyped in 3,124 type 2 diabetic subjects with high cardiovascular risk: the Noninsulin-Dependent Diabetes, Hypertension, Microalbuminuria, Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR) study. We used Cox regression analysis to estimate the impact of the TaqIB single nucleotide polymorphism on the CHD events (myocardial infarction or sudden death) during follow-up.<\/jats:p>\n               <jats:p>RESULTS\u2014The incidence of CHD was higher in B1B1 homozygotes than in B2 carriers (P = 0.02). This effect was mainly due to sudden death (hazard ratio [B1B1 vs. B2+] = 1.51 [95% CI = 1.05\u20132.18]). Although the B1 allele was associated in a dose-dependent fashion with lower HDL cholesterol (P &amp;lt; 0.001), the association with sudden death persisted after adjustment for multiple risk factors, including HDL cholesterol levels.<\/jats:p>\n               <jats:p>CONCLUSIONS\u2014In type 2 diabetic patients, the CETP TaqIB polymorphism is a good genetic predictor of cardiac mortality. This association is partly independent of the effect on HDL cholesterol levels.<\/jats:p>","DOI":"10.2337\/dc07-0869","type":"journal-article","created":{"date-parts":[[2007,10,26]],"date-time":"2007-10-26T16:15:43Z","timestamp":1193415343000},"page":"2863-2867","update-policy":"http:\/\/dx.doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":16,"title":["The CETP <i>Taq<\/i>IB Polymorphism Is Associated With the Risk of Sudden Death in Type 2 Diabetic Patients"],"prefix":"10.2337","volume":"30","author":[{"given":"Isabelle","family":"Porchay-Balde\u0301relli","sequence":"first","affiliation":[{"name":"Institut National de la Sante\u0301 et de la Recherche Me\u0301dicale, U695, Genetic Determinants for Type 2 Diabetes and Its Vascular Complications, Paris, France"},{"name":"University Paris-Diderot, Paris 7, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franck","family":"Pe\u0301an","sequence":"additional","affiliation":[{"name":"Institut National de la Sante\u0301 et de la Recherche Me\u0301dicale, U695, Genetic Determinants for Type 2 Diabetes and Its Vascular Complications, Paris, France"},{"name":"University Paris-Diderot, Paris 7, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nai\u0308ma","family":"Bellili","sequence":"additional","affiliation":[{"name":"Institut National de la Sante\u0301 et de la Recherche Me\u0301dicale, U695, Genetic Determinants for Type 2 Diabetes and Its Vascular Complications, Paris, France"},{"name":"University Paris-Diderot, Paris 7, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riphed","family":"Jaziri","sequence":"additional","affiliation":[{"name":"Institut National de la Sante\u0301 et de la Recherche Me\u0301dicale, U695, Genetic Determinants for Type 2 Diabetes and Its Vascular Complications, Paris, France"},{"name":"University Paris-Diderot, Paris 7, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Marre","sequence":"additional","affiliation":[{"name":"Institut National de la Sante\u0301 et de la Recherche Me\u0301dicale, U695, Genetic Determinants for Type 2 Diabetes and Its Vascular Complications, Paris, France"},{"name":"University Paris-Diderot, Paris 7, Paris, France"},{"name":"Department of Endocrinology, Diabetology, Nutrition and Metabolic Diseases, Assistance Publique-Ho\u0302pitaux de Paris, Xavier Bichat Hospital, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fre\u0301de\u0301ric","family":"Fumeron","sequence":"additional","affiliation":[{"name":"Institut National de la Sante\u0301 et de la Recherche Me\u0301dicale, U695, Genetic Determinants for Type 2 Diabetes and Its Vascular Complications, Paris, France"},{"name":"University Paris-Diderot, Paris 7, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the DIABHYCAR Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1167","reference":[{"doi-asserted-by":"crossref","unstructured":"Pyorala K, Laakso M, Uusitupa M: Diabetes and atherosclerosis: an epidemiological view. Diabetes Metab Rev\u20083: 463\u2013524, 1987","key":"2022031202505935200_R1","DOI":"10.1002\/dmr.5610030206"},{"doi-asserted-by":"crossref","unstructured":"Balkau B, Jouven X, Ducimetiere P, Eschwege E: Diabetes as a risk factor for sudden death. Lancet\u2008345: 1968\u20131969, 1999","key":"2022031202505935200_R2","DOI":"10.1016\/S0140-6736(99)04383-4"},{"doi-asserted-by":"crossref","unstructured":"Curb JD, Rodriguez BL, Burchfiel CM, Abbott RD, Chiu D, Yano K: Sudden death, impaired glucose tolerance, and diabetes in Japanese-American men. Circulation\u200891: 2591\u20132595, 1995","key":"2022031202505935200_R3","DOI":"10.1161\/01.CIR.91.10.2591"},{"doi-asserted-by":"crossref","unstructured":"Wilson PW: Established risk factors and coronary artery disease: the Framingham Study. Am J Hypertens\u20087: 7S\u201312S, 1994","key":"2022031202505935200_R4","DOI":"10.1093\/ajh\/7.7.7S"},{"doi-asserted-by":"crossref","unstructured":"Suarez GA, Clark VM, Norell JE, Kottke TE, Callahan MJ, O\u2019Brien PC, Low PA, Dyck PJ: Sudden cardiac death in diabetes mellitus: risk factors in the Rochester diabetic neuropathy study. J Neurol Neurosurg Psychiatry\u200876: 240\u2013245, 2005","key":"2022031202505935200_R5","DOI":"10.1136\/jnnp.2004.039339"},{"doi-asserted-by":"crossref","unstructured":"Dunn FL Hyperlipidemia in diabetes mellitus. Diabetes Metab Rev\u20086: 47\u201361, 1990","key":"2022031202505935200_R6","DOI":"10.1002\/dmr.5610060103"},{"doi-asserted-by":"crossref","unstructured":"Yamashita S, Hirano K, Sakai N, Matsuzawa Y: Molecular biology and pathophysiological aspects of plasma cholesteryl ester transfer protein. Biochim Biophys Acta\u20081529: 257\u2013275, 2000","key":"2022031202505935200_R7","DOI":"10.1016\/S1388-1981(00)00164-5"},{"doi-asserted-by":"crossref","unstructured":"Kuivenhoven JA, Jukema JW, Zwinderman AH, de Knijff P, McPherson R, Bruschke AV, Lie KI, Kastelein JJ: The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. N Engl J Med\u2008338: 86\u201393, 1998","key":"2022031202505935200_R8","DOI":"10.1056\/NEJM199801083380203"},{"doi-asserted-by":"crossref","unstructured":"Durlach A, Clavel C, Girard-Globa A, Durlach V: Sex-dependent association of a genetic polymorphism of cholesteryl ester transfer protein with high-density lipoprotein cholesterol and macrovascular pathology in type II diabetic patients. J. Clin Endocrinol Metab\u200884: 3656\u20133659, 1999","key":"2022031202505935200_R9","DOI":"10.1210\/jcem.84.10.6064"},{"doi-asserted-by":"crossref","unstructured":"Dachet C, Poirier O, Cambien F, Luc G, Chapman J, Rouis M: New functional promoter polymorphism, C-629A, in cholesteryl ester transfer protein (CETP) gene related to CETP mass and HDL cholesterol levels: role of Sp1\/Sp3 in transcriptional regulation. Arterioscler Thromb Vasc Biol\u200820: 507\u2013515, 2000","key":"2022031202505935200_R10","DOI":"10.1161\/01.ATV.20.2.507"},{"doi-asserted-by":"crossref","unstructured":"Boekholdt SM, Sacks FM, Jukema JW, Shepherd J, Freeman DJ, McMahon AD, Cambien F, Nicaud V, de Grooth GJ, Talmud PJ, Humphries SE, Miller GJ, Eiriksdottir G, Gudnason V, Kauma H, Kakko S, Savolainen MJ, Arca M, Montali A, Liu S, Lanz HJ, Zwinderman AH, Kuivenhoven JA, Kastelein JJ: Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13 677 Subjects. Circulation\u2008111: 278\u2013287, 2005","key":"2022031202505935200_R11","DOI":"10.1161\/01.CIR.0000153341.46271.40"},{"doi-asserted-by":"crossref","unstructured":"Kawasaki I, Tahara H, Emoto M, Shoji T, Nishizawa Y: Relationship between TaqIB cholesteryl ester transfer protein gene polymorphism and macrovascular complications in Japanese patients with type 2 diabetes. Diabetes\u200851: 871\u2013874, 2002","key":"2022031202505935200_R12","DOI":"10.2337\/diabetes.51.3.871"},{"doi-asserted-by":"crossref","unstructured":"Ordovas JM, Cupples LA, Corella D, Otvos JD, Osgood D, Martinez A, Lahoz C, Coltell O, Wilson PW, Schaefer EJ: Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study. Arterioscler Thromb Vasc Biol\u200820: 1323\u20131329, 2000","key":"2022031202505935200_R13","DOI":"10.1161\/01.ATV.20.5.1323"},{"doi-asserted-by":"crossref","unstructured":"Liu S, Schmitz C, Stampfer MJ, Sacks F, Hennekens CH, Lindpaintner K, Ridker PM, Liu S: A prospective study of TaqIB polymorphism in the gene coding for cholesteryl ester transfer protein and risk of myocardial infarction in middle-aged men. Atherosclerosis\u2008161: 469\u2013474, 2002","key":"2022031202505935200_R14","DOI":"10.1016\/S0021-9150(01)00673-6"},{"doi-asserted-by":"crossref","unstructured":"Fazio S, Linton MF: Sorting out the complexities of reverse cholesterol transport: CETP polymorphisms, HDL, and coronary disease. J Clin Endocrinol Metab\u200891: 3273\u20133275, 2006","key":"2022031202505935200_R15","DOI":"10.1210\/jc.2006-1264"},{"doi-asserted-by":"crossref","unstructured":"Borggreve SE, Hillege HL, Wolffenbuttel BH, de Jong PE, Zuurman MW, van der Steege G, van Tol A, Dullaart RP, PREVEND Study Group: An increased coronary risk is paradoxically associated with common cholesteryl ester transfer protein gene variations that relate to higher high-density lipoprotein cholesterol: a population-based study. J Clin Endocrinol Metab\u200891: 3382\u20133388, 2006","key":"2022031202505935200_R16","DOI":"10.1210\/jc.2005-2322"},{"doi-asserted-by":"crossref","unstructured":"Passa P, Chatellier G: The DIAB-HYCAR Study. Diabetologia\u200839: 1662\u20131667, 1996","key":"2022031202505935200_R17","DOI":"10.1007\/s001250050631"},{"doi-asserted-by":"crossref","unstructured":"Lie\u0300vre M, Marre M, Chatellier G, Plouin P, Re\u0301glier J, Richardson L, Bugnard F, Vasmant D: The Non-Insulin-Dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR) study: design, organization, and patient recruitment: DIABHYCAR Study Group. Control Clin Trials\u200821: 383\u2013396, 2000","key":"2022031202505935200_R18","DOI":"10.1016\/S0197-2456(00)00060-X"},{"doi-asserted-by":"crossref","unstructured":"Marre M, Lievre M, Chatellier G, Mann JF, Passa P, Menard J: Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ\u2008328: 495, 2004","key":"2022031202505935200_R19","DOI":"10.1136\/bmj.37970.629537.0D"},{"doi-asserted-by":"crossref","unstructured":"Hetet G, Elbaz A, Gariepy J, Nicaud V, Arveiler D, Morrison C, Kee F, Evans A, Simon A, Amarenco P, Cambien F, Grandchamp B: Association studies between haemochromatosis gene mutations and the risk of cardiovascular diseases. Eur J Clin Invest\u200831: 382\u2013388, 2001","key":"2022031202505935200_R20","DOI":"10.1046\/j.1365-2362.2001.00829.x"},{"doi-asserted-by":"crossref","unstructured":"Fumeron F, Betoulle D, Luc G, Behague I, Ricard S, Poirier O, Jemaa R, Evans A, Arveiler D, Marques-Vidal P, Bard JM, Fruchard JC, Ducimetiere P, Apfelbaum M, Cambien F: Alcohol intake modulates the effect of a polymorphism of the cholesteryl ester transfer protein gene on plasma high density lipoprotein and the risk of myocardial infarction. J Clin Invest\u200896: 1664\u20131671, 1995","key":"2022031202505935200_R21","DOI":"10.1172\/JCI118207"},{"doi-asserted-by":"crossref","unstructured":"Meguro S, Takei I, Murata M, Hirose H, Takei N, Mitsuyoshi Y, Ishii K, Oguchi S, Shinohara J, Takeshita E, Watanabe K, Saruta T: Cholesteryl ester transfer protein polymorphism associated with macroangiopathy in Japanese patients with type 2 diabetes. Atherosclerosis\u2008156: 151\u2013156, 2001","key":"2022031202505935200_R22","DOI":"10.1016\/S0021-9150(00)00606-7"},{"doi-asserted-by":"crossref","unstructured":"Relvas WG, Izar MC, Helfenstein T, Fonseca MI, Colovati M, Oliveira A, Ihara SS, Han SW, Las Casas AA, Fonseca FA: Relationship between gene polymorphisms and prevalence of myocardial infarction among diabetic and non-diabetic subjects. Atherosclerosis\u2008178: 101\u2013105, 2005","key":"2022031202505935200_R23","DOI":"10.1016\/j.atherosclerosis.2004.05.025"},{"doi-asserted-by":"crossref","unstructured":"Blankenberg S, Rupprecht HJ, Bickel C, Jiang XC, Poirier O, Lackner KJ, Meyer J, Cambien F, Tiret L: Common genetic variation of the cholesteryl ester transfer protein gene strongly predicts future cardiovascular death in patients with coronary artery disease. J Am Coll Cardiol\u200841: 1983\u20131989, 2003","key":"2022031202505935200_R24","DOI":"10.1016\/S0735-1097(03)00408-X"},{"doi-asserted-by":"crossref","unstructured":"Asselbergs FW, Moore JH, van den Berg MP, Rimm EB, de Boer RA, Dullaart RP, Navis G, van Gilst WH: A role for CETP TaqIB polymorphism in determining susceptibility to atrial fibrillation: a nested case control study. BMC Med Genet\u20087: 39, 2006","key":"2022031202505935200_R25","DOI":"10.1186\/1471-2350-7-39"},{"doi-asserted-by":"crossref","unstructured":"Jouven X, Desnos M, Guerot C, Ducimetie\u0300re P: Idiopathic atrial fibrillation as a risk factor for mortality: the Paris Prospective Study I. Eur Heart J\u200820: 896\u2013899, 1999","key":"2022031202505935200_R26","DOI":"10.1053\/euhj.1998.1397"},{"doi-asserted-by":"crossref","unstructured":"Benjamin EJ, Wolf PA, D\u2019Agostino RB, Silbershatz H, Kannel WB, Levy D: Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation\u200898: 946\u2013952, 1998","key":"2022031202505935200_R27","DOI":"10.1161\/01.CIR.98.10.946"},{"doi-asserted-by":"crossref","unstructured":"Klerkx AH, El Harchaoui K, van der Steeg WA Boekholdt SM, Stroes ES, Kastelein JJ, Kuivenhoven JA: Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis. Arterioscler Thromb Vasc Biol\u200826: 706\u2013715, 2006","key":"2022031202505935200_R28","DOI":"10.1161\/01.ATV.0000205595.19612.c9"},{"doi-asserted-by":"crossref","unstructured":"Barter PJ, Kastelein JJP: Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease. J Am Coll Cardiol\u200847: 492\u2013499, 2006","key":"2022031202505935200_R29","DOI":"10.1016\/j.jacc.2005.09.042"},{"doi-asserted-by":"crossref","unstructured":"Editorial: Cholesterol: the good, the bad, and the stopped trials. Lancet\u2008368: 2034, 2006","key":"2022031202505935200_R30","DOI":"10.1016\/S0140-6736(06)69815-2"},{"doi-asserted-by":"crossref","unstructured":"Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Tuzcu EM, ILLUSTRATE Investigators: Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med\u2008356: 1304\u20131316, 2007","key":"2022031202505935200_R31","DOI":"10.1056\/NEJMoa070635"},{"doi-asserted-by":"crossref","unstructured":"Tall AR: CETP inhibitors to increase HDL cholesterol levels: effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med\u2008356: 1364\u20131366, 2007","key":"2022031202505935200_R32","DOI":"10.1056\/NEJMe078029"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/30\/11\/2863\/594959\/zdc01107002863.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/30\/11\/2863\/594959\/zdc01107002863.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T02:51:11Z","timestamp":1647053471000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/30\/11\/2863\/4835\/The-CETP-TaqIB-Polymorphism-Is-Associated-With-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11,1]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2007,11,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc07-0869","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"type":"print","value":"0149-5992"},{"type":"electronic","value":"1935-5548"}],"subject":[],"published":{"date-parts":[[2007,11,1]]}}}